Type HI hyperlipoproteinemia is characterized by delayed chylomicron and VLDL remnant catabolism and is associated with homozygosity for the apoE-2 allele. We have identified a kindred in which heterozygosity for an apoE mutant, apoE-1 (Lys'4-+Glu), is dominantly associated with the expression of type III hyperlipoproteinemia. DNA sequence analysis of the mutant apoE gene revealed a single-point mutation that resulted in the substitution of glutamic acid (GAG) for lysine (AAG) at residue 146 in the proposed receptor-binding domain of apoE. The pathophysiological effect of this mutation was investigated in vivo by kinetic studies in the patient and six normal subjects, and in vitro by binding studies of apoE-1 (Lys "-+Glu) to LDL receptors on human fibroblasts and to heparin. The kinetic studies revealed that apoE-1(Lys46-Glu) was catabolized significantly slower than apoE-3 in normals (P < 0.005). In the proband, the plasma residence times of both apoEs were substantially longer and the production rate of total apoE was about two times higher than in the control subjects. ApoE-1 (Lys'6-÷Glu) was defective in interacting with LDL receptors, and its ability to displace LDL in an in vitro assay was reduced to 7.7% compared with apoE-3. The affinity of apoE-1 (Lys "-+Glu) to heparin was also markedly reduced compared with both apoE-2(Argl58-+Cys) and apoE-3.
Introduction
Human apoE is a constituent of several classes of plasma lipoproteins and plays an important role in modulating the catabolism of chylomicron and VLDL remnants by binding to LDL (apoB, apoE) and putative apoE (remnant) receptors on cell membranes (for reviews see references 1 and 2). The three major alleles of apoE code for the isoproteins apoE-2
Structural defects of the apoE may result in the expression of type III hyperlipoproteinemia (HLP),' which is characterized by an impaired chylomicron and VLDL remnant catabolism and the accumulation of cholesterol and apoE-enriched remnant particles (for reviews see references [6] [7] [8] . Type III HLP is most frequently associated with homozygosity for apo E-2(Arg '58-Cys), an isoprotein defective in its in vivo catabolism (9) and in vitro binding to LDL receptors (10) . However, homozygosity for the 1-2 allele is permissive for, but in 95% of the cases not associated with, the development of type III HLP, and other hyperlipidemic factors appear to contribute to the manifestation of this disease (11, 12) .
In contrast, five different apoE mutants have thus far been reported that are almost always associated with type III HLP, even in the heterozygous state, and have therefore been proposed to be inherited as autosomal dominant traits. ApoE-2(Lys '46Gln) was originally identified in two independent individuals ( 13 ) and has since been observed in three additional kindreds ( 14) . The double mutant apoE-3 (Cys II2-Arg, Arg 142-Cys) was described in one family, and all six heterozygotes were dysbetalipoproteinemic, even at the age of 2 years (15, 16) . Family studies in subjects with apoE-3 (Cys 12-+Arg, duplication of residues 120-126 or 121-127) identified 42 heterozygotes (17-20). All carriers of the mutated allele exhibited characteristics of type III HLP. Another mutant apoE, apoE-4(Glu 1 3-Lys,Arg 145-+Cys), was originally observed in a 24-y-old homozygous female with severe type III HLP (21). Analysis of first-degree relatives indicated that the occurrence of apoE-4(Glu 13-+Lys,Arg '45-Cys) is associated with an incomplete or partially dominant expression of a moderate form of this disease (22) .
The mutant apoE-1 (Lys "'-Glu) also leads to a dominant expression of type III HLP in all five affected patients heterozygous for the mutated allele (23, 24) . Since our initial description of this kindred, a second family with type III HLP due to the identical mutation has been identified in Japan (25) .
In this study, we have determined the structural defect in the apoE-1 (Lys 146-4Glu) gene and studied the functional impli- In vivo kinetic studies Study subjects. In addition to the patient described above, six healthy young adults, three males and three females, aged 19-23, were studied as controls. The six subjects had an apoE-3/3 phenotype, normal lipid levels for age and sex, normal fasting glucose concentrations, normal kidney, liver, and endocrine functions, and were taking no medications (Table I ). All normal volunteers and the proband from the Harrisburg kindred were studied as in-patients at the Clinical Center of the National Institutes of Health and gave informed consent to the study protocol, which was approved by the Institute Review Board of the National Heart, Lung, and Blood Institute.
ApoE isolation. ApoE-I(Lysl46-+Glu) was isolated from the proband, whereas apoE-2(Arg '58--Cys) and apoE-3 were purified from individuals homozygous for the respective alleles. VLDL was obtained by preparative ultracentrifugation (28, 29) Study protocol. The study subjects were placed on a defined isoweight diet (42% carbohydrate, 42% fat, 16% protein, 200 mg cholesterol/ 1,000 kcal, ratio polyunsaturated/saturated fat 0.2) 3 d before the start of the study. 1 d before injection, the subjects began to receive 900 mg potassium iodide per day given in equal doses three times a day with meals; this was continued through the end of the study. After the injection of "31I-apoE-3 and l'2I-apoE-I(Lys '4-)Glu), blood samples were obtained after 10 min, at 1, 3, 6, 12, 18, and 24 h, and every day until day 7. The exact amount of apoE injected was not calculated but was estimated to be < 1% of the total pool size and thus did not significantly affect steady state conditions. Samples were collected into tubes containing 0.1 % Na2EDTA, kept at 4°C, and plasma was obtained by low-speed centrifugation at 2,000 rpm for 30 min. Sodium azide (0.05%) and aprotinin (200 Kallikrein inhibitor U/ml; Boehringer Mannheim Biochemicals, Indianapolis, IN) were added to the plasma. Radioactivity was quantitated in a gamma counter (model Autogamma 5260; Packard Instruments Co., Downers Grove, IL).
Analytical methods. ApoE phenotypes were determined by isoelectric-focusing gel electrophoresis (33) , and apoE levels were quantitated by radioimmunoassay (34) . Plasma cholesterol and triglyceride concentrations were determined on an Abbott VPSS analyzer (Abbott Laboratories, North Chicago, IL). HDL cholesterol was measured after dextran sulfate precipitation of plasma (35) . The other lipid and lipoprotein analyses were performed as published (36). The residence time (RT) was determined from the area under the plasma decay curves using the computer-assisted curve-fitting program SAAM 29 (37). The fractional catabolic rate is the reciprocal of the RT. Production rates were calculated according to the following formula: production rate = (apoE concentration X plasma volume)/(RT x weight). The plasma volume was determined by dividing the total radioactivity injected by the radioactivity per unit volume in a sample obtained 10 min after injection. Intergroup comparisons were performed using Student's t test.
In vitro binding studies LDL displacement by apoE. To determine the LDL receptor-binding affinity of apoE-2, apoE-3, and the mutant apoE-1 (Lys '4-*Glu), their ability to displace radioiodinated LDL from receptors on normal human fibroblasts was quantitated. Normal fibroblasts were isolated and grown as previously described (38) . On day 0, cells were placed in 24-well plates (Costar Corp., Cambridge, MA) and maintained in growth medium (Eagle's minimal essential medium, 2 mM glutamine, 10% [v/v] FCS). On day 6, the FCS was replaced with 10% lipoproteindepleted serum to upregulate LDL receptors. 48 h later the cells were chilled to 40C for 20 min. The medium was replaced with medium containing 2.5 yg protein/ml 1"I-LDL and apoE liposomes in concentrations of 1, 2, 4, and 8 pg/ml (apoE-l(Lys' --Glu), apoE-2) or 0.1, 0.5, 1, 2, and 4 pg/ml (apoE-3), and the cells were incubated for an additional 4 h at 40C. The supernatant was collected, and the cells were washed and lysed with 0.1 N sodium hydroxide. Cell-associated radioactivity was quantitated by TCA precipitation of an aliquot of the lysed cells. Cell protein content was determined, and cell-associated LDL was calculated per microgram of cell protein (39) . The competition data were used to determine the apoE liposome concentration required to displace 50% of bound LDL. The inhibition of LDL binding by normal apoE-3 was defined as 100%, and the relative inhibition by apoE-1 (Lys '-*Glu) and apoE-2 was calculated (40).
The ligands used were prepared as follows: LDL in 10 M glycine (pH 10) was iodinated with iodine-125 (1 mCi/mg LDL) by the iodine monochloride method as modified for lipoproteins (41) . Specific activities ranged from 100 to 150 cpm/ng LDL, containing < 4% labeled lipid as determined by Folch extraction. ApoE-phospholipid complexes (apoE liposomes) were prepared as described by Havinga et al. (42) .
Heparin binding. Heparin-Sepharose CL 6B and Sepharose CL 6B were obtained from Pharmacia LKB Biotechnology Inc. (Piscataway, NJ) and prepared as recommended by the manufacturer. Heparin-binding assays were performed under nondenaturing and denaturing conditions.
For binding of radiolabeled apoE under nondenaturing conditions, 4 mg of heparin-Sepharose or 4 mg Sepharose was incubated for 4 h at 4°C in 200 M1 10 mM Tris-HCl, pH 7.5, 50 mM NaCl, and 1% BSA containing radioiodinated apoE liposomes (1 Isg protein/ml).
ApoE-l(Lys 6-Glu), apoE-2, and apoE-3 were radioiodinated (specific activity: 1,714-1,900 dpmlng) and packed into liposomes as described earlier. After incubation of the gel with the respective apoE, the gel matrix was sedimented by centrifugation at 10,000 g. The radioactivity in 100-td aliquots of the top and bottom fractions was quantitated, and the amount of gel-bound ligand was determined by subtracting the radioactivity of the top aliquot from that of the bottom aliquot. Heparin binding was corrected for nonspecific Sepharose binding by subtracting Sepharose gel-bound radioactivity and expressed as nanograms of apoE bound per microgram of heparin. The mass of heparin in heparin-Sepharose was quantitated by uronic acid determination (43).
For binding under denaturing conditions, the assay was modified as follows: the incubation buffer consisted of 5 M urea, 2 mM NaH2PO4 x H20/Na2HPO4 x 7H20, pH 7.8, 50mM NaCl, and 1% BSA. Radiolabeled apoE-1 (Lys '--+Glu), apoE-2, and apoE-3 (1 yg protein/ml) were used as ligands.
Results
Structural analysis. To determine the underlying mutation in apo E-1Harrisbur, genomic DNAs from the proband and from a control subject with the phenotype apoE-3/3 were amplified by PCR using apoE-specific primers. Sequence analysis revealed a single base exchange of a G for an A at position 254 within exon 4 of the apoE gene, which results in the substitution of lysine (AAG) by glutamic acid (GAG) at amino acid position 146 in the proposed receptor-binding domain of apoE. The other allele was found to be normal, thus establishing that the patient is a heterozygote for the I-I(Lys '--.Glu) allele.
In vivo kinetic studies. Six normal subjects with an apoE-3/3 phenotype and the proband participated in the in vivo kinetic study. The lipid and lipoprotein profiles of the participants are shown in Table I . Radiolabeled '"I-apoE-1 (Lys '4-Glu) and 13'I-apoE-3 were injected simultaneously, and blood samples were obtained at intervals through day 7. Steady state conditions during the study were demonstrated by multiple determinations of plasma apoE levels (data not shown). Radioactivity was quantitated at each time point, plasma decay curves were plotted, and residence times were calculated using computerassisted curve fitting. The catabolism of apoE-1 (Lys"46-+Glu) and apoE-3 in one of the normal subjects is illustrated in Fig. 1 A, representative for the six controls studied. ApoE-1-(Lys "'--Glu) was catabolized significantly slower (RT, 0.91 d) than apoE-3 (RT, 0.66 d) in all normal subjects (P < 0.005). The proband, in contrast, catabolized both apoE-1 (Lys "-+Glu) (RT, 3.76 d) and normal apoE-3 (RT, 2.32 d) much slower than did the controls (Fig. 1 B) . The kinetic parameters of radiolabeled apoE-I(Lys '-4Glu) and apoE-3 are summarized The lipoprotein distribution of '"I-apoE-1 (Lys '-+Glu) and '3'I-apoE-3, analyzed 10 min after injection by sequential ultracentrifugation of plasma samples of two normal subjects and of the proband, was very similar, as shown in Table III . However, in contrast to the controls, the majority of apoE-1 (Lys lteGlu) and apoE-3 accumulated in the VLDL subfraction of the proband. Fibroblast binding. To assess the LDL receptor affinity of apoE-l (Lys '4-Glu) as compared with apoE-2 and apoE-3, the ability of the different apoE isoproteins to displace LDL from LDL receptors on normal human fibroblasts was determined. ApoE liposomes were used for these in vitro competition assays to exclude apoB-LDL receptor interactions. Normal human fibroblasts were incubated with 2.5 tzg/ml LDL and increasing concentrations of liposomes containing either apoE-1 (Lys"-+ Glu), apoE-2, or apoE-3. The apoE liposome concentration required to displace 50% LDL (IC50) was calculated, and the receptor affinities of apoE-1 (Lys '-+Glu) and apoE-2 were expressed relative to normal binding of apoE-3. Binding of apoE-3 was defined as 100%. Both apoE-I(Lys'4--Glu) and apoE-2 were comparably defective in their ability to displace LDL from receptors on normal human fibroblasts (apoE-1 (Lys"-+ Glu): 7.7±0.8%; apoE-2: 8.5±1.0%, Table IV) .
Heparin binding. To investigate further the interaction of apoE-l (Lys l4-+Glu) and apoE-2(Arg '58-*Cys) with polyanionic binding sites similar to the LDL (apoB, apoE) receptor, heparin was used as a model for negatively charged cell surface proteoglycans. Under nondenaturing conditions, the amount of apoE-1 (Lys '-+Glu) and apoE-2 bound to heparin-Sepharose was decreased to 10 and 60%, respectively, compared with the amount of apoE-3 bound (Fig. 2 A) . Denaturation of the apoEs with 5 M urea restored the ability of apoE-2 to bind to heparin-Sepharose, while apoE-I(Lys 46--Glu) remained defective (Fig. 2 B) .
Discussion
We have previously described a kindred in which heterozygosity for an apoE mutant, apoE-1 (Lys '-+Glu), is dominantly associated with the expression of type III HLP (23) . In the present study, we investigated this mutant apoE by sequence (24) .
To assess the metabolic effect of this mutation, an in vivo kinetic study was performed by simultaneously injecting 125I1 apoE-1 (Lys '-+Glu) and '3'1-apoE-3 into the proband and into six normal volunteers (Table II) . In the control subjects, apoE-1 (Lys'46-Glu) was catabolized significantly slower than was apoE-3; in the proband, both residence times were markedly prolonged. These results demonstrate that apoE-I (Lys '-+Glu) not only has an impaired in vivo metabolism but also interferes with the catabolism of apoE-3, thus leading to a greatly prolonged residence time of the normal E isoprotein in the patient. In addition, there was an approximately twofold increase in the production rate of apoE-1 (Lys '--+Glu) compared with its normal counterpart (Table II) . In the patient, therefore, the -10 times elevated plasma apoE levels were due to both a decreased fractional catabolic rate and an increase in apoE production. Previously performed kinetic studies of apoE-2-(Arg'58--Cys) also showed a decased fractional rate for apoE-2 (9) as an experimental correlate of impaired function. However, the defect of apoE-1 appears more severe, because it results in dominant manifestation of disease as opposed to the recessive mode observed for apoE-2. One possible explanation is that the LDL receptor-binding affinity of apoE-l (Lys t4+Glu) is lower than that of apoE-2. However, this is not the case. ApoE-2 and apoE-1 (Lys '-+Glu) were both shown to possess 8% of normal receptor-binding activity in an in vitro competition assay using apoE liposomes. Thus, differential binding of apoE-l " and apoE-2 to the LDL receptor binding does not discriminate between dominant and variable manifestation of type HI HLP. This conclusion is supported by the data recently published by Moriyama et al. (25) . His group reported that ApoE-l (Lys'46-Glu), which was isolated from a Japanese proband and complexed with dimyristoylphosphatidylcholine, bound to the LDL receptor with less than 10% of the affinity of normal apoE-3. With the exception of apoE-2(Arg '58--Cys), which has a receptor-binding activity as low as 1% (10), apoE-l(Lys'40_ Glu) is the most binding-defective naturally occurring apoE mutant described. In comparison, the binding activities of apoE-3 (Cys "2-+Arg,Arg '42_*Cys), apoE-3 (duplication of residues 120-126), and apoE-2(Lys46-+Gln) were -20, 25, and 35-40%, respectively, compared with apoE-3 (13, 18, 44) . The latter mutant demonstrates the importance not only of the position of the mutated residue, but also of the charge of the newly introduced amino acid on LDL receptor-binding activity. The substitution of the basic residue 146, lysine, by the polar amino acid glutamine in apoE-2(Lys '-+Gln) and by the negatively charged glutamic acid in apoE-1 (Lys "6-{Glu) occurs in the center of the proposed receptor-binding domain of apoE, which contains six positively charged amino acids. A three dimensional crystallographic analysis of this domain revealed that residue 146, lysine, is directed toward the aqueous phase and is not involved in forming salt bridges within the apoE molecule, thus being available for intermolecular interactions with acidic residues of the LDL receptor (45) . A substitution at this position is expected to adversely affect binding by directly altering the ionic interactions between ligand and receptor.
Based on the fact that several apoEs are present on a single lipoprotein particle, multiple interactions between apoE molecules and its receptors may be necessary (oligomeric ligandreceptor interaction). This concept is supported by data from Nykjaer et al. (46) , who showed that it is the dimeric form of lipoprotein lipase that mediates binding of #5-VLDL to LRP.
Thus the binding-defective apoE mutant would prevent the formation of the required number of ionic interactions of the exposed apoE on the particle surface with its receptor, even in the presence of normal apoE-3 (Fig. 3) . This would explain why the proband from the Harrisburg kindred catabolized both apoE-1 (Lys '46-Glu) and apoE-3 much slower than did the normal controls, resulting in the accumulation in plasma of particles containing both mutant and normal apoE. The especially slow removal from circulation of the mutant apoE and its twofold increased production rate and secretion, compared with the normal counterpart, explains the predominance in plasma of apoE-I(Lys 1-+Glu) over normal apoE-3 at a ratio of approximately 3:1 and the increased pool size of lipoproteins with low receptor affinity. In addition, apoE-1 (Lys "6-Glu) may associate preferentially with chylomicrons and VLDL. The enrichment of VLDL particles with binding-defective apoE-3 (Cys "2-Arg,Arg '42-*Cys) and apoE-3 (duplication of residues 120-126) has already been proposed to promote the expression of type III HLP (44, 47) . Our data, however, indicate that apoE-1 (Lys "-+Glu) and apoE-3 distribute equally well to all lipoprotein classes in both normal subjects and in the proband (Table III) . The predominant association of both apoE with the VLDL subfraction of the proband is explained by the high levels of VLDL accumulating in the patient's plasma due to the delayed catabolism of apoE-1 (Lys '-+Glu). Since VLDLs readily acquire added apoE, the enrichment of these particles with apoE appears to be a symptom of type III HLP rather than a consequence of an increased affinity of the mutant apoE for triglyceride-rich lipoproteins.
To investigate further LDL receptor-independent ionic interactions of apoE with cell membranes, we analyzed the binding of apoE-3, apoE-2(Arg '58-Cys), and apoE-1 (Lys 46--Glu) to heparin as a model for cell surface proteoglycans. There are two heparin-binding sites in the apoE molecule (48, 49) , and one is contained within the region of the molecule implicated in LDL receptor binding (amino acids [135] [136] [137] [138] [139] [140] [141] [142] [143] [144] [145] [146] [147] [148] [149] [150] . The replacement of residue 142, arginine, by cysteine in apoE-3 (Cys "2-Arg,Arg 142-+Cys) has already been shown to result in a weaker affinity for heparin as measured by salt gradient elution (44) .
We could show that the binding of apoE-I(Lys '4-*Glu) was reduced to 10% of apoE-3, whereas the affinity of apoE-2 was it is not a change in the three-dimensional conformation of apoE-l (Lys '-4Glu) but rather the charge shift in the linear amino acid sequence that seems responsible for its low affinity to heparin. This finding agrees with previously performed chemical modification experiments demonstrating the importance of positively charged arginine and lysine residues in the binding of apoB and apoE to heparin (50) . It is interesting that the opposite appears to true for apoE-2(Arg"'58-Cys). This result corroborates earlier studies which demonstrated that the severe binding defect of apoE-2 is due mainly to conformational changes (44, 51 teoglycans on the cell surface and, in a second step, be presented to LDL or apoE (remnant) receptors, which in turn mediate the cellular uptake of these particles (53, 58) . In addition, binding of apoE-to heparan sulfate proteoglycans could bring triglyceride-and apoE-rich particles into close spatial relationship with lipolytic enzymes (hepatic lipase, reference 59, lipoprotein lipase: reference 60), thereby enhancing hydrolysis of triglycerides as well as cellular binding and uptake of these lipoproteins. Nascent apoE may also become bound to proteoglycans inside the cell and then be transported to the membrane, where they serve as an apoE reservoir for the uptake of lipoproteins (61, 62). Defective proteoglycan binding of apoE may thus result in ineffective retardation of apoE on the cell surface with an apparently higher rate of secretion. In our kinetic study, the production rate of the mutant apoE-1 was indeed increased twofold, compared with apoE-3, which would be in accordance with the proposed mechanism. However, direct measurements of transcriptional or secretional levels could not be done because a liver biopsy would have been required.
At least two other apoE mutants associated with dominant expression of type HI HLP, apoE-2(Lys '--*Gln) and apoE-4(Glu '3-+Lys,Arg 145--Cys), are also impaired in their binding to heparin. Ji et al. (63) recently showed that defective binding of apoE variants to heparan sulfate proteoglycan paralleled defective remnant binding, mediated by the respective apoE variant in vitro. It was concluded from this study that defective binding of apoE to proteoglycans may correlate with the expression of type III HLP. Following these data, together with the presented results of our in vivo kinetic studies, heparin binding, in addition to plasma apoE levels (22) , may be used to differentiate between recessive and dominant apoE mutants.
In conclusion, in vitro binding assays and in vivo turnover studies demonstrate that the dominant expression of type III HLP associated with apoE-1 (Lys '-4Glu) is due to (a) an overexpression of the mutated allele, (b) an impaired binding of the mutant apoE to LDL receptors, and (c) a slow removal from the plasma compartment of particles containing both mutant and normal apoE. Defective binding of apoE-I(Lys'6-. Glu) to heparin or heparin-like proteoglycans may play a significant role in the manifestation of this disease. Our combined data indicate that dominantly transmitted type III HLP is a multifactorial disorder of apoE metabolism.
